Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Unilateral Vocal Cord Motion Impairment After 1 Dose of Vincristine: Case Report and Literature Review.

Aaron H, Azadarmaki R, Lango MN.

Am J Ther. 2015 Mar 3. [Epub ahead of print]

PMID:
25738569
2.
3.

Metastatic cervical carcinoma from an unknown primary: literature review.

Arrangoiz R, Galloway TJ, Papavasiliou P, Ridge JA, Lango MN.

Ear Nose Throat J. 2014 Apr-May;93(4-5):E1-10. Review.

PMID:
24817234
4.

Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer.

Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA.

Cancer. 2014 Mar 15;120(6):840-7. doi: 10.1002/cncr.28482. Epub 2013 Dec 18.

5.

Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.

Doss M, Kolb HC, Walsh JC, Mocharla V, Fan H, Chaudhary A, Zhu Z, Alpaugh RK, Lango MN, Yu JQ.

J Nucl Med. 2013 Dec;54(12):2087-92. doi: 10.2967/jnumed.113.119800. Epub 2013 Oct 17.

6.

p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.

Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA.

Head Neck. 2014 Dec;36(12):1677-84. doi: 10.1002/hed.23514. Epub 2014 Jan 13.

PMID:
24115269
7.

Dysplasia at the margin? Investigating the case for subsequent therapy in 'low-risk' squamous cell carcinoma of the oral tongue.

Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ.

Oral Oncol. 2013 Nov;49(11):1083-7. doi: 10.1016/j.oraloncology.2013.08.001. Epub 2013 Sep 17.

8.

Malignant transformation of respiratory papillomatosis in a solid-organ transplant patient: case report and literature review.

Azadarmaki R, Lango MN.

Ann Otol Rhinol Laryngol. 2013 Jul;122(7):457-60. Review.

PMID:
23951698
9.

Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer.

Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein-Szanto AJ.

Head Neck. 2014 Aug;36(8):1113-9. doi: 10.1002/hed.23421. Epub 2013 Oct 26.

PMID:
23804308
10.

Informational Needs of Head and Neck Cancer Patients.

Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA.

Health Technol (Berl). 2012 Apr 1;2(1):57-62. Epub 2012 Feb 14.

11.

Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA.

Head Neck. 2013 Feb;35(2):160-4. doi: 10.1002/hed.22929. Epub 2012 Feb 2.

12.

Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.

Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ.

Am J Clin Oncol. 2010 Dec;33(6):599-603. doi: 10.1097/COC.0b013e3181c4c3cc.

PMID:
21063195
13.

Surgery in the multimodality treatment of sinonasal malignancies.

Lango MN, Topham NS, Perlis CS, Flieder DB, Weaver MW, Turaka A, Patel SA, Ridge JA.

Curr Probl Cancer. 2010 Sep-Oct;34(5):304-21. doi: 10.1016/j.currproblcancer.2010.07.001. Review. No abstract available.

PMID:
20851263
14.

Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer.

Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ.

Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):65-70. doi: 10.1016/j.ijrobp.2009.10.034. Epub 2010 Apr 10.

15.

Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation.

Lango MN, Egleston B, Ende K, Feigenberg S, D'Ambrosio DJ, Cohen RB, Ahmad S, Nicolaou N, Ridge JA.

Head Neck. 2010 Mar;32(3):341-7. doi: 10.1002/hed.21188.

16.

Multimodal treatment for head and neck cancer.

Lango MN.

Surg Clin North Am. 2009 Feb;89(1):43-52, viii. doi: 10.1016/j.suc.2008.09.018. Review.

PMID:
19186230
17.

Controversies in surgical management of the node-positive neck after chemoradiation.

Lango MN, Myers JN, Garden AS.

Semin Radiat Oncol. 2009 Jan;19(1):24-8. doi: 10.1016/j.semradonc.2008.09.005. Review.

PMID:
19028342
18.

Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis.

Lango MN, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J, Ridge JA.

Head Neck. 2009 Mar;31(3):328-37. doi: 10.1002/hed.20976.

PMID:
18853450
19.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

20.

Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.

Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR.

J Natl Cancer Inst. 2002 Mar 6;94(5):375-83.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk